Hereditary Predisposition Plays a Larger Role in SCLC Development Than Previously Recognized and May Inform Personalized Treatment

Promising Results for Lurbinectedin in SCLC When Paired with Irinotecan

Benefit to Pembrolizumab Observed in Previously Treated Malignant Pleural Mesothelioma Irrespective of PD-L1 Status

Treatment of Immunotherapy-Related Ophthalmic Toxicities: An Interview With Dr. Asim V. Farooq

Understanding and Targeting SCLC

KRAS: Old Target, New Hope

Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs

Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?

Mutation or Amplification: Who MET the Expectations?

RET Therapy for NSCLC, a New Generation of Inhibitors

The Multitude of Options for First-Line Therapy for EGFR-Mutated Lung Cancer

The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy